IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.301
Volume 3, Issue 2, December 2023

Ocular Drug Delivery System

Nikita Jadhav, Ms. Pratiksha Gosavi, Dr. Gajanan Sanap
Department of Pharmacy
LBYP College of Pharmacy, Chhatrapati Sambhajinagar, Maharashtra, India

Abstract: *The projected advent of new medications with short biological half-lives, whose efficacy may depend on a more continuous drug supply than eyedrops can offer, is one reason why innovative ocular drug delivery methods are currently garnering more consideration. moreover due to the possibility for various delivery methods to lessen the negative effects of the Recently released or currently being researched medications with increased potency. certain ophthalmic delivery systems improve corneal absorption to prolong the period of medication activity; These systems include hydrophilic ocular inserts, soluble gels and emulsions, and ion-pair Prodrugs, connections, and liposome. This paper's goal is to review antibiotic formulations intended for ocular delivery. Initially, the ocular barriers and their anatomy and physiology were explained. Topical formulations include contact lenses, ophthalmic inserts, hydrogels, eye drops, and ointments. created in a follow-up section to describe the ocular administration and the presently available quantity format. Lastly, a summary of current developments in the administration of antibiotics to the eyes is given. Not in vivo and Studies conducted in vivo examined the effectiveness of antibacterial compounds. various combinations and configurations are created to lengthen the period of time that antibiotics remain in the eye, enhance their absorption, and the reaction of therapy. The ability to keep the drug at a therapeutic level at the site of action is the greatest obstacle to ocular medicine. In this eye care procedure, illnesses interfere with one's ability to concentrate effectively. This method of delivering drugs to the eyes is hindered by the obstacles that shield the eyes. The active ingredient's bioavailability The main obstacle is the pharmacological substance. Current delivery is optimal for ocular therapies because Comparing the lesser dose needed to the systemic use due to its quick start of action. Topical absorption in this case is this trans-corneal approach to the inner regions of the eye permeation is thought to be the drug's main route of action.*

Keywords: Ophthalmic drug insert, ocular therapy , precorneal.

I. INTRODUCTION

Ophthalmic preparations are specialised sterile dosage forms that can be delivered intravenously (intraocularly), topically , intraocularly or periocularly (near the eye), or in conjunction with an ophthalmic topically. A majority the Solutions, suspensions, and ointments are frequently used dosage forms. Poor Precorneal loss factors play the major role in the bioavailability of the medications from a ocular dosage forms. which include tear dynamics, lacrimation, solution drainage, tear dilution, and tear turnover Conjunctival absorption, ineffective absorption, temporary cul-de-sac habitation, and The main difficulties are caused by the corneal epithelial membrane's relative impermeability. Various Strategies à for ocular medication administration are taking up the consideration, ranging from fundamental formulation increasing the accessibility of pharmaceuticals. Most commonly, ODDS can be manufactured as gels, ointments[1].There are many different types of new ocular drug delivery systems, such as liposomes, nanoparticles, niosomes, nanoemulsions, and microemulsions. In situ gelling systems are among them. They can target a particular spot, work well with hydrophilic or lipophilic medicines, and can be administered in many paths. When the right excipients are used, in situ gelling devices can raise the precorneal residence period and lessen the medication loss brought on by the rip. various polymers and preparation techniques Chemical compositions enable the nanoparticles to address topical, periocular, and mucoadhesion needs or intraocular administration, and to create a formulation that is stable, efficient, and non-irritating for the sufferer [(2)] . Pharmacies find ocular medicine delivery to be the most intriguing and appealing. However, pharmaceutical scientists have a difficult battle. The therapeutic effect of this antiquated ophthalmic solution, ointment, and suspension dosage forms is no longer met. as essential to some of the

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.301
Volume 3, Issue 2, December 2023

deadly diseases of today. This ODDS, or ocular drug delivery system, is the majority of the difficult work that pharmaceutical researchers do. These eye care There are formulations in sterile, isotonic, and buffered solutions. For the eye medication, There are various dose forms available for the formulation. This ocular medication delivery method The eye's structure and physiology are based on a special, intricate, and dissimilar structure[3].

II. ANATOMY OF EYE

Sclera :-

The strong white sheath that makes up the ball's outer layer is known as the sclera (the white part of the eye). It is a strong fibrous membrane that preserves the eye's form as a roughly sphere-shaped object. It is significantly thicker towards the eye's posterior/rear portion as opposed to the anterior or front of the eye[4]

Conjunctiva B:

A thin layer of translucent mucus makes up the conjunctiva. The interior of the eyelids, and the epithelial barrier a third from the front of the eyeball. The appropriate portion are referred to as the palpebral and bulbar of conjunctiva. conjunctiva. Two layers make up the conjunctiva: an outer layer and outer epithelium and the stroma beneath it (substantia) Proper).The eye's visible surface consists of the cornea and conjunctiva are covered by tear film[4].

Cornea:

The cornea is made up of three layers, including the stroma, endothelium, and epithelium, as well as a mechanical barrier that prevents foreign materials from entering the eye. Every layer has a unique polarity and a structure that limits the rate at which drugs can permeate it. The ocular tight connections are established and the epithelium has a lipophilic tendency to limit paracellular drug leaking through the tear film[5].

Aqueous humour :- The fluid known as aqueous humour resembles jelly. placed in the eye's front/outer chamber. Immediately behind the cornea and in front of the iris, the "anterior chamber of the eye" is filled with a watery fluid. The aqueous humour is very faintly salty alkaline. solution containing trace amounts of sodium and chloride ions. Continuous production is made, primarily by the ciliary. passes through the posterior chamber from the vena cava enters the anterior chamber and leaves throughput the trabecular both the uveoscleral path and the route at an angle[6].



Fig:1 Human Eye[7]

Pupil :

Although the pupil often looks to be the black "centre" of the eye, it is actually the circular iris's central opening, through which light travels into the pupil. The size of the pupil (and consequently the quantity of the amount of light that enters the eye) is controlled by the "Light reflex" (also known as the pupillary reflex)[8].

Iris :

The iris is a small, circular contractile veil that is situated in the behind the cornea but in front of the lens. Iris is an eye. A diaphragm with a range of sizes whose purpose is to adjusting the pupil's size will control how much light is admitted into the pupil. The colourful portion of the eye (shades may vary) individually variations[8].

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.301
Volume 3, Issue 2, December 2023

Retina :

The innermost, light-sensitive layer of tissue in the retina of most vertebrates and certain mollusks is called the retina . In order to produce visual perception, the optic nerve in the eye focuses light into a two-dimensional image on the retina. The retina then interprets the image and transmits nerve impulses to the visual cortex via the optic nerve. The purpose of the retina is similar to that of a camera's film or image sensor in many aspects[9].

Choroid / Bruch's Membrane :

For the purpose of supplying the blood to the retina, the choroid is one of the body's most highly vascularized tissues. Humans have relatively large (20–40 um) and fenestrated choroidal capillary endothelial cells. With time, Bruch's membrane (BM) thickens. These adjustments lead to increased cross-linking of collagen fibres, increased calcification of elastic fibres, and increased Glycosaminoglycans are turned over[10].

Blood Ocular Barrier :-

They stop foreign substances from entering the bloodstream. They are divided into two categories: the blood-retinal barrier (BRB) and the blood-aqueous barrier (BAB). BAB is the front part of the eye that restricts several chemicals' entry in the intraocular environment. BAB facilitates the transport of tiny and lipophilic medicines. These medications leave the anterior compartment more quickly than bigger, hydrophilic ones. For instance, it was discovered that the clearance rate of pilocarpine more quickly than inulin[11].

Tear :- A tear can affect the ophthalmic medication that is delivered by binding to it, improving its clearance, and diluting it. One of the dynamic barriers that considerably reduces drug availability and obstructs its therapeutic efficacy is tear turnover[12].

III. ROUTES OF OCULAR DRUG DELIVARY

Subconjuctival Administration

The medication is administered to the mucus membrane, which covers the exposed part of the eyeball and the inside surface of the eyelids, via the subconjunctiva route[13].

Supera choroidal

The space the choroid and the sclera is known as the suprachoroidal space. These are the methods for administering the medication to the eye's suprachoroidal area[13].

Topical Administration

only used for topical ocular drug administration; nevertheless, their duration of contact with the eye surface is brief. The interaction, and hence The length of a drug's activity can be extended through formulation design (such as gels, formulations for gelification, ointments, and insertions)[14].

Intravitreal Administration

Intravitreal drug delivery via single injections or during vitrectomy has emerged as a successful method for therapeutic drug delivery. An instantaneous and enhanced therapeutic effect at the targeted tissue is the benefit of this focused drug delivery. first reported the use of intravitreal injections in 19112 to tamponade a retinal rupture using an intravitreal air bubble. intravitreal administration of antibiotics, such as penicillin or sulphanilamide[16].



Fig-2 : Routes of ocular drug delivery[15]

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.301
Volume 3, Issue 2, December 2023

Intracameral Injection :-

During intracameral injections, an antibiotic is injected straight into the anterior part of the eyeball or in the ocular cavity. It is typically carried out after cataract surgery in order to prevent endophthalmitis brought on by a virus of the eye that may develop following cataract surgery. The use of intracameral injection in the management of glaucoma has recently Using hydrogel functionalized with thiol and vinyl sulfone groupings was released[17].

Iontophoresis :-

One method for delivering drugs to the posterior portion of the eye is iontophoresis. It calls for the use of voltage inclination. Innovative systems entail the hiring various devices based on microneedles. They'd increased the quantity of formula applied to the retina in comparison to injection of suprachoroidal[18].

Systemic Administration:-

The main barriers for the anterior and posterior segments of the ocular medication delivery system are typically the blood-aqueous barrier and the blood-retinal barrier[19].

Ocular Formulations:-

Top of Form

Bottom of Form

Eye Drop :- Over 95% of the marketed ocular products are eye drops. The medicine is injected into the front portion of the eye. Among their benefits are simplicity in management and agreed-upon stability. But among their drawbacks are low retention period (less than five minutes), low bioavailability, and significant adverse effect brought about by the regular use of high focused attention[20].

Eye Suspensions :- Some of the challenges in order to a formulator needs to prevail in the midst of the non-homogeneity of a suspension's progress of the visual measurements (cake, settling, structure) growth, gathering of the suspended particles, effective preservation, reusability, and simplicity in manufacturing. Suspensions are being used stable but not thermodynamically unstable frameworks, bearing in mind that they were left alone for a lengthy duration, lead[21].



Table -1 : Ocular dosage form [22]

Eye Emulsion :- It is advantageous to use an emulsion-based ocular detailing technique to increase the medication's bioavailability and dissolvability. Two different types of ocular emulsions that are used commercially are pharmaceuticals that are dynamic vehicles: (1) oil in water in oil (w/o) emulsion and (2) water (o/w) structures. o/w for the visual dosage structure Emulsion is fundamental and typically preferred in much of w/o structure. Many researches have verified the effectiveness of emulsions in improving precorneal home time, administering medication, and drug corneal penetration leak and related issues enhancing the bioavailability of vision[23].

Eye Ointment:- Semisolid formulations meant for external application are called eye ointments. They are typically made with semisolid mixes and solids that have melted or become softer sites that are about body temperature and are

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.301
Volume 3, Issue 2, December 2023

not eye irritating. Ointments may be easy either complex or base-like. After implementation in to the ointment splits into tiny droplets in the eye and continue to serve as a drug depot in the dead end long durations. Thus, ointments are helpful in enhancing the bioavailability of drugs and maintaining drug discharge. Despite being secure and well-tolerated ointments suffer from comparatively poor patient compliance as a result of visual impairment and occasional annoyance[24].

Hydro gels :- High molecular weight hydrophilic copolymers or cross-linked polymers that form a three-dimensional network in water are the building blocks of hydrogels. It is demonstrated that the gels combine notably longer cul de-sac dwell periods correlated with higher medication bioavailability. Customary cellulose derivatives are among the gelling agents. Hyaluronic acid, carbomer, and PVA. Such Patients are more likely to accept systems since they are injected as a solution into the eyes. Subsequently, they transform into gels. These systems' polymers demonstrate reversible change in phase. The shift in Viscosity may result from a pH shift both ionic strength and temperature[25,26].

Eye powder :- These are water-sensitive medication dose forms in sterile, solid form. Cefuroxime, moxifoxacin, and voriconazole are administered as injectables through intracameral injection. In saline, cefuroxime and moxifoxacin are reconstituted. while water is used to reconstitute voriconazole. The solutions of voriconazole and cefuroxime remain steady for seven days following reformulation. Moxifoxacin solution, however, is stable for two months [27,28].

Ophthalmic Insert :- Ocular inserts are made of flexible polymeric materials that are inserted between the eyeball's sclera and the lid in the cul-de-sac of the conjunctiva. They were found in 1971 [29] and are non-allergic, sterile, insoluble in tear fluid, and biologically inactive. This form was created in an effort to improve ocular bioavailability and long-lasting medication effects by lengthening the duration of drug-tissue contact the pupil. They also enhance patient compliance and lessen systemic absorption. Lens inserts do not require preservatives [30].

Contact Lenses :- The system of contact lenses is circulated. It is a thin, circular, curved piece of transparent plastic that is applied straight to the eye's surface. They are employed to lengthen the medication's duration of residence in the eye [31].

In- situ Gel :- It is anticipated that this ocular drug delivery system will use an easy-to-handle device to administer a precise concentration of the medicine over a predetermined period of time. The goal of this novel medicinal dosage form method is to integrate the benefits of gels and solutions. They are deposited as a solution into their conjunctival sac in their in-situ gels, where they undergo a transition into the gel brought on by a change in either temperature or ion focused effort or Ph. Numerous polymers possess these characteristics[32].

Table -2 : Ocular insert device [33-36]

Name	Discretion
Ocular medication soluble insert	Compact oval wafer, made of soluble copolymers of ethyl and actyl soften upon insertion acetate.
Collagen barriers	Collagen cross- link province sclera makes up eroded discs.
Accuserts	A reservoir is enclosed by a flat, flexible, elliptical insoluble Device made of two layers pilocarpine is delivered for seven days through commercial use.
Small-disc or optical	Framework curved hydrophilic or hydrophobic disc with a diameter 4-5mm.
	Rose-shaped hydroxy propyl cellulose device used to treat eye problem instead than crying.
Laurel	A hydrophilic polymer solution free of preservatives that is freeze-dried on the trip of soft hydrophobic carrier strip ; hydrate in tear strip right away.
Dessicated flakes	Gel foam slabs loaded with medication and cetyl ester wax combination in chloroform.
Gel foam	Solid polyvinyl alcohol flag with medication attached, affixed to a paper handle application, the medication is released as the flag separates and progressively dissolved.
New method of delivering eye medication	

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.301
Volume 3, Issue 2, December 2023

Approaches to improve ocular Bioavailability :-

Penetration enhancer :- Like acting filament inhibitors, surfactants, bile salts, chelators and organic compounds have been used to increase the bioavailability of topically applied peptides and proteins are otherwise poorly absorbed due to unfavourable molecular size, charge, hydrophilic as well as their susceptibility to the degradation by peptidases in the eye They acts as increasing corneal uptake by modifying the integrity of corneal epithelium. Chelating agent, surfactants, preservatives, and bile salts were studied as possible penetration enhancer . Penetration enhancer have also been reported to reduce the drop size of conventional opthalmic solutions especially if they do not elicit local irritation[37].

Viscosity enhancers:- A variety of polymers are employed in ocular medication formulations to increase viscosity. Additionally , they lengthen the precorneal residence time, which increases the drug's transcorneal penetration into the anterior chamber. In this consistency, Enhancers increase bioavailability while having little negative effects on people. Polyvinyl alcohol (PVA), methylcellulose, and polyvinylpyrrolidone are the polymers utilised in this. (PVP), hydroxypropyl cellulose, hydroxyethylcellulose, and HPMC. Organic polymers like xanthum gum, veegum, and HA are also utilised as viscosity enhancers[38].

A Barrier to Ocular drug delivery system :- The primary drawback of systemic administration of ocular medicines is that only 1 to 2% of the prescribed dose reaches the anterior segment due to the limited ocular bioavailability. Consequently, these ocular clinical practises illnesses affecting the cornea, conjunctiva, and sclera, which make up the anterior portion of the eye, uvea anterior, etc. the method of applying the medications topically has been chosen to supervision. There are a few obstacles that must be addressed for this to be the best administrative path. overcome biological, metabolic, and physicochemical obstacles to arrive at the desired location of action.20][39].

Fig:3-ocular Drug Barrier[40].

Advantages of ocular delivery :-

1. To distribute drugs in a regulated and sustained manner.
2. To extend the corneal contact period in order to enhance the drug's ocular bioavailability. Effective adhesion to the corneal surface can accomplish this.To target within the ocular globe in order to stop other ocular tissues from being lost.
3. To get across the barriers that protect, such as lacrimation, drainage, and Conjunctival remove absorption. To make the patient more comfortable, increase patient compliance, and enhance the medication's therapeutic efficacy.
4.To offer an improved housing for the delivery system[41].

Disadvantages of ocular delivery :-

1. In an emergency, dosage form termination is not possible.
2. It interfere with vision .

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.301
Volume 3, Issue 2, December 2023

3.It is difficult to install and take out.
4.The third is sporadic loss while rubbing eyes or sleeping[42].

Application :

1. Encapsulation of cells

Encapsulated cell technology (ECT) is the trapping of immunologically isolated cells with fibres or microcapsules prior to their delivery into the eye.It makes it possible to deliver therapeutic proteins to the posterior areas of the eye in a regulated, continuous, and long-term manner. The polymer implant that has human RPE cells that have undergone genetic modification secretes ciliary neutrophic factor into the vitreous humour of the patient.

2. Genetic treatment

Gene therapy techniques are employed in conjunction with tissue engineering to treat blindness caused by glaucoma, cataracts, and other conditions affecting the eyes. Adenovirus, retrovirus, adenoassociated virus, and herpes simplex virus are among the several viruses that are modified for use in gene transfer and gene therapy applications. Ocular gene transfer via topical application is the fastest method. The utilisation of improved delivery systems extends the duration of the vector's contact with the ocular surface, potentially improving transgene expression and facilitating non-invasive administration[43].

3. Protein and peptides Therapy :-

Another major obstacle to distribution is the low membrane permeability and high molecular weight of proteins and peptides across ocular tissues and barriers. Owing to these challenges, the most popular way to deliver drugs based on proteins and peptides is now by very invasive intravitreal injection[44].

4. The topical administration of ophthalmic medications for the treatment of a variety of ocular conditions, including glaucoma, ocular hypertension, allergies, inflammation, and dry eyes, has made extensive use of polyoxyethylated nonionic surfactants. These surfactants can be used in micellar solution and emulsion dosage forms [45].

IV. CONCLUSION

For scientists working in the sector, developing effective treatments for ocular illnesses is a daunting task. Inserts collagen shields, disposable contact lenses, ocular films, and other formulations are part of a novel ophthalmic delivery system. This ocular delivery methods include the A more recent trend combines drug delivery technologies to enhance the therapeutic impact or therapeutic outcome of a successful medication. These perfect setups need to have medication concentration that is effective at the target tissue. This tended era at the very least systemic outcome. A comfortable design is greatly improved by patient acceptance. medication delivery system for eyes. Significant advancements are needed in the long-term medication stability, larger-scale production, and release. Here, the ocular medication delivery mechanism of ocserts offer numerous benefits, including enhanced patient .

REFERENCES

[1]. Thakur RR. Modern Delivery Systems for Ocular Drug Formulations: A Comparative Overview W.R.T Conventional Dosage Form. Int. J . Res. In. Phar & Biomed Sci, 2011; 2 (1): 8-18.
[2]. Remington, L.A. Clinical anatomy and physiology of the visual system, 3rd ed.; Elsevier/Butterworth Heinemann: St. Louis, MO, USA, 2012; ISBN 978-1-4377-1926-0 .
[3]. Fujiwara T, Margolis R.; Slakter J.S.; Spaide R.F. Enhanced depth imaging optical coherence tomography of the choroid in highly myopic eyes. Am. J. Ophthalmol. Vol 148, 2009, 445-450.
[4]. Urtti A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev, 58, 2006, 1131–35
[5]. Wilson CG, Zhu YP, Kurmala P, Rao LS, Dhillon B. Opthamic drug Delivery.In: Anya M.Hillery, Andrew W.Lloyd James Swabrick (eds.), Drug Delivery and targeting, Taylor and Francis e-library, London,2005;298-318.
[6]. Jtirvinena K, Tomi J, Urttia SA. Ocular absorption following topical delivery. Adv Drug Deliv Rev, 16, 1995, 3-19.
[7]. https://www.sciencedirect.com/topics/medicine-and-dentistry/intravitreal-administration .

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.301
Volume 3, Issue 2, December 2023

[8]. Nanjawade BK, Manvi FV, Manjappa AS. In situ-forming hydrogels for sustained ophthalmic drug delivery. J Control Release, 122, 2007, 119–34.
[9]. https://en.m.wikipedia.org/wiki/Retina
[10]. Wilson CG, Zhu YP, Kurmala P, Rao LS, Dhillon B. Opthamic drug Delivery.In: Anya M.Hillery, Andrew W.Lloyd James Swabrick (eds.), Drug Delivery and targeting, Taylor and Francis e-library, London,2005;298-318
[11]. Singh M, Bharadwaj S, Lee KE, Kang SG. Therapeutic nanoemulsions in ophthalmic drug administration: concept in formulations and characterization techniques for ocular drug delivery. J Control Release. 2020;328:895-916. https://doi.org/ 10.1016/j.jconrel.2020.10.025.
[12]. Gaudana R, Ananthula HK, Parenky A, Mitra AK. Ocular Drug Delivery. AAPS J. 2010 May 1;12(3):348–60.
[13]. Van der Bijl P, van Eyk AD, Meyer D, Effects of three penetration enhancers on transcorneal permeation of cyclosporine. Cornea, 2001;20:505-508
[14]. https://images.app.goo.gl/tsUUqTFHLG632GsS9
[15]. Meqi SA, Deshpande SG. Ocular drug delivery: Controlled and novel drug delivery. New delhi:CBS Publishers; 2002, p 82-84.
[16]. https://www.sciencedirect.com/topics/medicine-and-dentistry/intravitreal-administration
[17]. Chan KC, Yu Y, Ng SH, Mak HK, Yip YWY, van der Merwe Y, et al. Intracameral injection of a chemically cross-linked hydrogel to study chronic neurodegeneration in glaucoma. Acta Biomater. 2019;94:219–31. https://doi.org/10.1016/j.actbio.2019.06.005.
[18]. Jung JH, Chiang B, Grossniklaus HE, Prausnitz MR. Ocular drug delivery targeted by iontophoresis in the suprachoroidal space using a microneedle. J Control Release. 2018;277:14–22. https://doi.org/10.1016/j.jconrel.2018.03.001
[19]. Burgalassi S, Chetoni P. Monti D, Saettone MF, Cytotoxicity of potential ocular permeation enhancers evaluated on rabbit and human corneal epithelial cell lines, Toxicol Lett. 2001;122; 1-2.
[20]. Maulvi FA, Soni TG, Shah DO. A review on therapeutic contact lenses for ocular drug delivery. Drug Deliv. 2016;23(8):3017–26. https://doi.org/10.3109/10717544.2016.1138342
[21]. Achouri D, Alhanout K, Piccerelle P, Andrieu V. Recent advances in ocular drug delivery. Drug development and industrial pharmacy. 1;39 (11)(2013 Nov) 1599-617. https://images.app.goo.gl/GpHhwtF4exYUYC367
[22]. Gote V, Sikder S, Sicotte J, Pal D. Ocular Drug Delivery: Present Innovations and Future Challenges. Journal of Pharmacology and Experimental Therapeutics. 1 (2019 Jan) j100-119.
[23]. Sasaki H, Yamamura K, Mukai T, Nishida K, Nakamura M. Enhancement of ocular penetration. Critical reviews on therapeutic drug carrier systems.
[24]. Meseurger G, Gurny R,Buri P, Rozier A, Plazonnet B. 1993.Gamma scientigraphic study of precorneal drainage and assessment of miotic response in rabbits of various Opthalmic formulations containing pilocarpine. International journal of pharmaceutics 1993; 95: 229-234.
[25]. .Gurny, H.Ibrahim and P.buri, The development and use of insitu formed gels triggered by pH-in biopharmaceutics of ocular drug delivary",Edman,P., CRS PRESS, (1993), pp. 81-90.
[26]. Nguyen ET, Shorstein NH. Preparation of intracameral antibiotics for injection. J Cataract Refract Surg. 2013;39(11):1778–9. 27.https://doi.org/10.1016/j.jcrs.2013.08.036.
[27]. Heralgi MM, Badami A, Vokuda H, Venkatachalam K. An update on voriconazole in ophthalmology. Of Sci J Delhi Ophthalmol Soc.2016;27(1):915.
[28]. Higuchi, T. Ocular Insert. U.S. Patent 3,630,200 A, 28 December 1971.
[29]. Kumari, A.; Sharma, P.; Garg, V.; Garg, G. Ocular inserts—Advancement in therapy of eye diseases. J. Adv.Pharm. Technol. Res. 2010, 1, 291. [CrossRef] [PubMed]
[30]. Baranowski, P.; Karolewicz, B.; Gajda, M.; Pluta, J. Ophthalmic drug dosage forms: Characterisation and research methods. Sci. World J. 2014, 2014, 1–14. [CrossRef] [PubMed].
[31]. Vandamme TF, Microemulsions as ocular drug delivery system: recent development and future challenges. Prog Retin Eye Res, 2002: 21: 15-34.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.301
Volume 3, Issue 2, December 2023

[32]. Sampath K, Bhowmik D, Harish G, Duraivel S and kumar P. (2013). Ocular Inserts: A Novel Controlled Drug Delivery System. The Pharma Innovation Journal, 1(12), 1-16.
[33]. Saettone MF, Salminen L. (2015). Ocular inserts for topical delivery. Advanced Drug Delivery, 16, 95–106.
[34]. Sahane NK, Banarjee SK, Gaikwad DD, Jadhav SL and Throat RM. (2010). Ocular Inserts- A Review. Drug Invention, 2, 57–64.
[35]. Duvvuri S, Majumdar S and Mitra AK. (2003). Drug delivery to the retina: challenges and opportunities. Expert Opinion and Biological Therapeutics, 3, 45-56.
[36]. A Textbook of Novel drug delivery systems by author Dr. Gajanan s.sanap, Ms Pranali P. Hatwar .
[37]. Lee VH. (2012). Precorneal, Corneal and Postcorneal factors. In: Mitra AK (Ed.). Ophthalmic Drug
[38]. Keister JC, Cooper ER, Missel PJ, Lang JC and Huger DF.(1991). Limits on optimizing ocular drug delivery. Journal of pharmaceutical sciences, 80, 50-3.
[39]. https://images.app.goo.gl/7nn5nK3yEDWepvmh6
[40]. Arul kumaran KSG, Karthika K and Padmapreetha J. (2010). Comparative review on conventional and advanced ocular drug delivery formulations, International Journal of Pharmacy and Pharmaceutical Sciences, 2, 1.
[41]. Lee, S.S.; Hughes, P.M.; Robinson, M.R. Recent advances in drug delivery systems for treating ocular complications of systemic diseases. Curr. Opin. Ophthalmol. 2009; 20: 511-519.
[42]. Vyas SP, Khar RK,Ed.Targeted and controlled drug delivery, CBS Publishers, New delhi,2011:374-375.
[43]. Renukuntla J, Vadlapudi AD, Patel A, Boddu SH, Mitra AK. Approaches for enhancing oral bioavailability of peptides and proteins. *International journal of pharmaceutics*. 2013;447:75–93. [PMC free article] [PubMed] [Google Scholar]
[44]. https://doi.org/10.1016/j.addr.2008.09.002